KOD News and Press, Kodiak Sciences Inc From 11/16/20

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration − On track for DAZZLE primary endpoint last patient last visit in late 2021 and topline results in early 2022 − Over 550 pat...

Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting PR Newswire PALO ALTO, Calif., Nov. 11, 2020 PALO ALTO, Calif. , Nov. 11, 2020 /PR...

Kodiak Sciences (KOD): Q3 GAAP EPS of -$0.80 misses by $0.12.cash equivalents and marketable securities of $380.5MPress Release For further details see: Kodiak Sciences EPS misses by $0.12

Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif., Nov. 9, 2020 PALO ALTO, Calif. , Nov. 9, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company com...

KOD has an excellent medium-long term bullish setup. Price is likely near completion of the strongest part of the rally. A short term pullback of 20-30% is expected after a 94% rally in one month to a key target level. For further details see: Riding The StockWaves: Tech...

Opthea has filed proposed terms to raise capital from a U.S. IPO. The firm is developing a treatment for Wet AMD and other eye conditions. OPT has produced impressive Phase 2b efficacy trial results for its lead candidate, so the IPO is worth considering for long-term hold life sc...

Kodiak Sciences reports initiation of Phase 3 trial of KSI-301. Incyte announces peptide-centric strategic collaboration with Nimble. AMAG receives a setback as the FDA rejects Makena. For further details see: Kodiak Initiates Phase 3 Trial, And Other News: The Good, Bad...

Kodiak Sciences (KOD) has announced that the first patients have been treated in three Phase 3 studies of KSI-301, an anti-VEGF antibody biopolymer conjugate, in treatment-naïve patients with diabetic macular edema (GLEAM and GLIMMER studies) and macular edema due to retinal vein oc...

Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion - Concurrent development program compares Kodiak's long-acting anti-VEGF antibody biopolymer conjugate K...

Graybug Vision (GRAY) has priced its upsized initial public offering of 5.628M (from 4.79M) at $16, at the midpoint of the expected range of $15-$17.Underwriters' over-allotment is an additional 843,750 shares.Trading kicks-off today on the Nasdaq Global Market.Offering is expected ...